Jacquelynne Cervantes-Torres, Carlos Cabello-Gutiérrez, Dolores-Adriana Ayón-Núñez, Gloria Soldevila, Roxana Olguin-Alor, Georgina Diaz, Gonzalo Acero, René Segura-Velázquez, Leonor Huerta, Isabel Gracia-Mora, Laura Cobos, Mayra Pérez-Tapia, Juan C Almagro, Francisco Suárez-Güemes, Raúl J Bobes, Gladis Fragoso, Edda Sciutto, Juan Pedro Laclette
Several COVID-19 vaccines use adenovirus vectors to deliver the SARS-CoV-2 spike (S) protein. Immunization with these vaccines promotes immunity against the S protein, but against also the adenovirus itself. This could interfere with the entry of the vaccine into the cell, reducing its efficacy. Herein, we evaluate the efficiency of an adenovirus-vectored vaccine (chimpanzee ChAdOx1 adenovirus, AZD1222) in boosting the specific immunity compared to that induced by a recombinant receptor-binding domain (RBD)-based vaccine without viral vector...
January 27, 2024: Applied Microbiology and Biotechnology